Endocrine Abstracts

Introduction: The management of patients with neuroendocrine neoplasms (NEN) has been revolutionised since the introduction of radiolabelled somatostatin analogues targeting overexpressed somatostatin receptors (SSTR). Accurate assessment of SSTR status of primary focus/metastases is crucial to determine the choice of the treatment method. Recently it has been shown that novel molecular probes, SST2-antagonists, recognize more binding sites in comparison to the wide...

Introduction: The good expression of somatostatin receptors in neuroendocrine tumor tissue enables effective treatment with peptide receptor radionuclide therapy (PRRT). To date, there is no clear consensus on the optimal PRRT arrangement due to the possibility of the use of different radiopharmaceutical regimens. In theory, the simultaneous use of two radionuclides (90Y and 177Lu) with different energy and radiation ranges should be more effective than monotherapy. The main o...